


Rabia Usman, Arshad Khan*, Moamen S. Refat, Ghaferah H. Al-Hazmi and Nongyue He*

Synthesis and crystal structure of (2*E*,2'*E*)-3,3'-(1,3-phenylene)bis(1-(3-bromophenyl)prop-2-en-1-one), C₂₄H₁₆Br₂O₂



<https://doi.org/10.1515/ncrs-2021-0139>

Received April 12, 2021; accepted May 4, 2021;

published online May 7, 2021

Abstract

C₂₄H₁₆Br₂O₂, orthorhombic, *Pnma* (no. 62), *a* = 7.407(3) Å, *b* = 44.336(16) Å, *c* = 6.046(2) Å, *V* = 944.8(3) Å³, *Z* = 4, *R*_{gt}(*F*) = 0.0602, *wR*_{ref}(*F*²) = 0.1315, *T* = 293 K.

CCDC no.: 1981826

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1: Data collection and handling.

Crystal:	Colorless block
Size:	0.20 × 0.14 × 0.10 mm
Wavelength:	Mo Kα radiation (0.71073 Å)
μ:	4.10 mm ⁻¹
Diffractometer, scan mode:	φ and ω
θ _{max} , completeness:	25.0°, 98%
<i>N</i> (<i>hkl</i>) _{measured} , <i>N</i> (<i>hkl</i>) _{unique} , <i>R</i> _{int} :	7399, 1779, 0.109
Criterion for <i>I</i> _{obs} , <i>N</i> (<i>hkl</i>) _{gt} :	<i>I</i> _{obs} > 2 σ(<i>I</i> _{obs}), 1183
<i>N</i> (<i>param</i>) _{refined} :	130
Programs:	Bruker [1], SHELX [2], Diamond [3]

Source of material

The target compound (2*E*,2'*E*)-3,3'-(1,3-phenylene)bis(1-(3-bromophenyl)prop-2-en-1-one) (PBP) was synthesized according to the procedure reported in ref. [4]. A base catalyzed condensation of 3-bromoacetophenone (2 equivalents) and isophthalaldehyde (1 equivalent) in ethanol in presence of NaOH at room temperature resulted in the PBP in good yield (85%). Good quality colorless block crystals were obtained by slow evaporation of the ethyl acetate solution.

Experimental details

The hydrogen atoms bonded to the carbon atoms were placed in calculated positions and refined as riding mode, with C–H = 0.96 Å with *U*_{iso}(H) = 1.2 *U*_{eq}(C).

***Corresponding authors:** Arshad Khan, State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing, 210096, P. R. China; and School of Materials Science and Engineering, Hunan University, Changsha, 110016, P. R. China; and Nongyue He, State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing, 210096, P. R. China, E-mail: arshadkhan@seu.edu.cn (A. Khan), nyhe1958@163.com (N. He). <https://orcid.org/0000-0001-8716-4312>

Rabia Usman, State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, Southeast University, Nanjing, 210096, P. R. China
Moamen S. Refat, Department of Chemistry, College of Science, Taif University, P. O. Box 11099, Taif, 21944, Saudi Arabia
Ghaferah H. Al-Hazmi, Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	U _{iso} [*] /U _{eq}
Br1	0.33707 (10)	0.02317 (2)	0.33389 (13)	0.0622 (3)
O1	0.2911 (8)	0.14332 (10)	0.4304 (8)	0.0741 (17)
C1	0.3569 (8)	0.05838 (12)	0.1574 (11)	0.0453 (15)
C2	0.4218 (10)	0.05592 (15)	−0.0586 (12)	0.0562 (18)
H2	0.4492	0.0371	−0.1185	0.067*
C3	0.4440 (10)	0.08155 (16)	−0.1802 (12)	0.062 (2)
H3	0.4919	0.0804	−0.3221	0.074*
C4	0.3962 (10)	0.10920 (14)	−0.0943 (11)	0.0521 (18)
H4	0.4084	0.1264	−0.1809	0.063*
C5	0.3299 (9)	0.11171 (13)	0.1196 (11)	0.0474 (16)
C6	0.3108 (9)	0.08564 (12)	0.2468 (12)	0.0467 (16)
H6	0.2672	0.0868	0.3908	0.056*
C7	0.2874 (10)	0.14117 (13)	0.2288 (13)	0.0519 (18)
C8	0.2396 (10)	0.16735 (13)	0.0899 (12)	0.0548 (18)
H8	0.2185	0.1647	−0.0604	0.066*
C9	0.2267 (9)	0.19450 (12)	0.1772 (11)	0.0479 (16)
H9	0.2527	0.1960	0.3273	0.057*
C10	0.1760 (9)	0.22249 (12)	0.0655 (11)	0.0452 (15)
C11	0.0960 (9)	0.22306 (13)	−0.1432 (11)	0.0491 (16)
H11	0.0694	0.2050	−0.2140	0.059*
C12	0.0554 (13)	0.2500	−0.2467 (17)	0.054 (3)
H12	0.0010	0.2500	−0.3853	0.065*
C15	0.2110 (12)	0.2500	0.1673 (14)	0.041 (2)
H15	0.2598	0.2500	0.3090	0.050*

Comment

Chalcones are well known organic compounds and a major component of some natural products, which have attracted immense interest owing to their characteristic biological activities namely, anti-cancer [5], anti-microbial [6], anti-inflammatory [7], anti-protozoal [8], anti-oxidant [9] and anti-malarial [10] etc. The presence of the double bond believe to impart bioactive characteristic to the chalcone and removal of double bonds will make them biological inactive. Structural modification, biological active and facile preparation are some of the characteristics that differentiate chalcones from the plethora of other bioactive molecules. The crystals of the PBP were subjected to single crystal X-ray diffraction (SXRD) to determine the non-covalent forces and molecular stacking in the solid state. The crystal structure of the title compound is mainly established by the hydrogen bonds C4–H4...O1 (2.615 Å) between two neighboring molecules to form a sheet like structure along the *a* axis. Additionally, C12–H12... π interaction (2.740 Å) along *c* keeps the stack together. Thus, these two different interactions enhance each other, and in turn stabilize the overall crystal structure. All parameters are in expected ranges [11].

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This research was financially supported by the National Key Research and Development Program of China (2017YFA0205301), NSFC (61701176) & Taif University Researches Supporting Project number (TURSP-2020/01), Taif University, Taif, Saudi Arabia.

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SAINT, APEX2 and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2009.
2. Sheldrick G. M. Crystal structure refinement with SHELXL. *Acta Crystallogr.* 2015, *C71*, 3–8.
3. Brandenburg K. *DIAMOND*. Visual Crystal Structure Information System, Ver. 4.0; Crystal Impact: Bonn, Germany, 2015.
4. Bhale P. S., Dongare S. B., Chanshetti U. B. Synthesis and antimicrobial screening of chalcones containing imidazo [1,2-*a*] pyridine nucleus. *Res. J. Chem. Sci.* 2013, *3*, 38–42.
5. Varmus H. The new era in cancer research. *Science* 2006, *312*, 1162–1165.
6. Mai C. W., Yaeghoobi M., Abd-Rahman N., Kang Y. B., Pichika M. R. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure–activity relationship analysis and regulation of apoptotic proteins. *Eur. J. Med. Chem.* 2014, *77*, 378–387.
7. Kant R., Kumar D., Agarwal D., Gupta R. D., Tilak R., Awasthi S. K., Agarwal A. Synthesis of newer 1,2,3-triazole linked chalcone and flavone hybrid compounds and evaluation of their antimicrobial and cytotoxic activities. *Eur. J. Med. Chem.* 2016, *113*, 34–49.
8. Bano S., Javed K., Ahmad S., Rathish I., Singh S., Chaitanya M., Arunasree K., Alam M. Synthesis of some novel chalcones, flavanones and flavones and evaluation of their anti-inflammatory activity. *Eur. J. Med. Chem.* 2013, *65*, 51–59.
9. Nazarian Z., Emami S., Heydari S., Ardestani S. K., Nakhjiri M., Poorrajab F., Shafiee A., Foroumadi A. Novel antileishmanial chalconoids: synthesis and biological activity of 1-or 3-(6-chloro-2H-chromen-3-yl) propen-1-ones. *Eur. J. Med. Chem.* 2010, *45*, 1424–1429.
10. Aly M. R. E. S., Fodah H. H. A. E. R., Saleh S. Y. Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes. *Eur. J. Med. Chem.* 2014, *76*, 517–530.
11. Yadav N., Dixit S. K., Bhattacharya A., Mishra L. C., Sharma M., Awasthi S. K., Bhasin V. K. Antimalarial activity of newly synthesized chalcone derivatives in vitro. *Chem. Biol. Drug Des.* 2012, *80*, 340–347.